Financial Comparison: Can-Fite BioPharma (NYSE:CANF) and Generex Biotechnology (OTCMKTS:GNBT)

Can-Fite BioPharma (NYSE:CANF) and Generex Biotechnology (OTCMKTS:GNBT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, profitability and earnings.

Risk & Volatility

Can-Fite BioPharma has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Generex Biotechnology has a beta of -0.07, suggesting that its share price is 107% less volatile than the S&P 500.

Insider and Institutional Ownership

21.0% of Can-Fite BioPharma shares are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by company insiders. Comparatively, 35.2% of Generex Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Can-Fite BioPharma and Generex Biotechnology, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Can-Fite BioPharma	0	0	2	0	3.00
Generex Biotechnology	0	0	0	0	0.00

Can-Fite BioPharma presently has a consensus price target of $14.50, indicating a potential upside of 2,953.27%. Given Can-Fite BioPharma’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Can-Fite BioPharma is more favorable than Generex Biotechnology.

Earnings & Valuation

This table compares Can-Fite BioPharma and Generex Biotechnology”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Can-Fite BioPharma	$560,000.00	3.00	-$7.63 million	($1.79)	-0.27
Generex Biotechnology	$2.66 million	0.00	-$33.33 million	N/A	N/A

Can-Fite BioPharma has higher earnings, but lower revenue than Generex Biotechnology.

Profitability

This table compares Can-Fite BioPharma and Generex Biotechnology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Can-Fite BioPharma	N/A	N/A	N/A
Generex Biotechnology	N/A	N/A	N/A

Summary

Can-Fite BioPharma beats Generex Biotechnology on 6 of the 8 factors compared between the two stocks.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

About Generex Biotechnology

Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and test kits and cassettes for testing infectious diseases, as well as Excellagen, a wound conforming gel. Further, the company is developing immunotherapeutic products and vaccines; and extracellular matrix hydrogel solution, a tissue engineered therapy for the treatment of Ulcerative Colitis. Additionally, it manufactures and sells foot and ankle surgical kits that include plates, screws, and tools; and distributes surgical supplies, orthopedic implants, artificial joints, and biologics, medical devices, and regenerative medicine products. It also serves as the general partner of the Management Services Organization. Generex Biotechnology Corporation was founded in 1983 and is headquartered in Miramar, Florida. On April 23, 2022, an involuntary petition for liquidation under Chapter 7 was filed against Generex Biotechnology Corporation in the U.S. Bankruptcy Court for the Southern District of Florida. On June 6, 2022, the involuntary petition was approved by the Court.